Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer
Background and aim: Radiotherapy (RT) plays a key role in the control of locally advanced non-small cell lung cancer (LA-NSCLC). Throughout the years, different doses and fractionations of RT have been used in an attempt to optimize the results. Recently, special interest has been given to hypofractionation (hypoRT) and stereotactic body radiation therapy (SBRT). HypoRT is a relatively widespread treatment, although the accompanying level of evidence is limited. For its part, SBRT has been used specially to overdose specific areas of the disease as a boost after radiochemotherapy. In both cases, the study of how to integrate these RT tools with chemotherapy and immunotherapy is fundamental. In addition, the 2020 covid-19 pandemic situation has sparked increased interest in hypofractionated treatments. In this review, we analyse the role of SBRT and hypoRT in the management of LA-NSCLC in accordance with current scientific evidence.
Relevance for patients: The objective of this article is to introduce professionals to the role that hypoRT and SBRT can play in the treatment of LA-NSCLC to offer the best treatment to their patients.
[1] Antonia SJ, Chiappori A, Gray JE, Villegas A, Mekhail T, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018;379:2342-50.
[2] Zhu X, Hou R, Li X, Jiang C, Xia W, Fu X. Predictive Model of the First Failure Pattern in Patients Receiving Definitive Chemoradiotherapy for Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC). Radiat Oncol 2020;15:43.
[3] Grass GD, Naghavi AO, Abuodeh YA, Perez BA, Dilling TJ. Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer 2019;20:e1-7.
[4] van Diessen JN, Chen C, van den Heuvel MM, BelderbosJS, Sonke JJ. Differential Analysis of Local and Regional Failure in Locally Advanced Non-small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. Radiother Oncol 2016;118:447-52.
[5] van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al. Randomized Controlled Trial of Resection Versus Radiotherapy after Induction Chemotherapy in Stage IIIA-N2 Non-small-cell Lung Cancer. J Natl Cancer Inst 2007;99:442-50.
[6] Scagliotti GV, Pastorino U, Vansteenkiste JF, Spaggiari L, Facciolo F, Orlowski TM, et al. Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-smallcell Lung Cancer. J Clin Oncol 2012;30:172-8.
[7] Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy Plus Chemotherapy with or Without Surgical Resection for Stage III Non-small-cell Lung Cancer: A Phase III Randomised Controlled Trial. Lancet 2009;374:379-86.
[8] Yoo C, Yoon S, Lee DH, Park SI, Kim DK, Kim YH, et al. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection. Clin Lung Cancer 2015;16:e203-12.
[9] National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (version 2.2019); 2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ nscl.pdf.
[10] Faivre-Finn C, Vicente D, Kurata T, Planchard D, PazAres L, Vansteenkiste JF, et al. LBA49 Durvalumab after Chemoradiotherapy in Stage III NSCLC: 4-Year Survival Update from the Phase III PACIFIC Trial. Ann Oncol 2020;31 Suppl 4:S1178-9.
[11] European Medicines Agency. Imfinzi (Durvalumab) An Overview of Imfinzi and why it is Authorised in the EU; 2018. Available from: https://www.ema.europa.eu/en/ documents/overview/imfinzi-epar-medicine-overview_ en.pdf. [Last accessed on June 2020].
[12] Kong FM, Ten Haken RK, Schipper MJ, Sullivan MA, Chen M, Lopez C, et al. High-dose Radiation Improved Local Tumor Control and Overall Survival in Patients with Inoperable/Unresectable Non-small-cell Lung Cancer: Long-term Results of a Radiation Dose Escalation Study. Int J Radiat Oncol Biol Phys 2005;63:324-33.
[13] Rengan R, Rosenzweig KE, Venkatraman E, Koutcher LA, Fox JL, Nayak R, et al. Improved Local Control with Higher Doses of Radiation in Large-volume Stage III Non-small-cell Lung Cancer. Int J Radiat Oncol Biol Phys 2004;60:741-7.
[14] Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, et al. Primary Analysis of the Phase II Component of a Phase I/II Dose Intensification Study Using Threedimensional Conformal Radiation Therapy and Concurrent Chemotherapy for Patients with Inoperable Non-small-cell Lung Cancer: RTOG 0117. J Clin Oncol 2010;28:2475-80.
[15] Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, et al. Pulmonary Toxicity in Stage III Nonsmall Cell Lung Cancer Patients Treated with High-dose (74 Gy) 3-Dimensional Conformal Thoracic Radiotherapy and Concurrent Chemotherapy Following Induction Chemotherapy: A Secondary Analysis of Cancer and Leukemia Grou. Int J Radiat Oncol Biol Phys 2011;81:1-6.
[16] Rosenman JG, Halle JS, Socinski MA, Deschesne K, Moore DT, Johnson H, et al. High-dose Conformal Radiotherapy for Treatment of Stage IIIA/IIIB Non-smallcell Lung Cancer: Technical Issues and Results of a Phase I/II Trial. Int J Radiat Oncol Biol Phys 2002;54:348-56.
[17] MacHtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, et al. Higher Biologically Effective Dose of Radiotherapy is Associated with Improved Outcomes for Locally Advanced Non-small Cell Lung Carcinoma Treated with Chemoradiation: An Analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2012;82:425-34.
[18] Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose Versus High-dose Conformal Radiotherapy with Concurrent and Consolidation Carboplatin Plus Paclitaxel with or without Cetuximab for Patients with Stage IIIA or IIIB non-smallcell Lung Cancer (RTOG 0617): A Randomised, Two-byTwo Factorial p. Lancet Oncol 2015;16:187-99.
[19] Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2017;12:293-301.
[20] Eaton BR, Pugh SL, Bradley JD, Masters G, Kavadi VS, Narayan S, et al. Institutional Enrollment and Survival among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. J Natl Cancer Inst 2016;108:1-8.
[21] Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of Intensity-modulated Radiation Therapy Technique For Locally Advanced Non-small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol 2017;35:56-62.
[22] Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, et al. Cardiac Toxicity after Radiotherapy for Stage III Non-small-cell Lung Cancer: Pooled Analysis of Dose-escalation Trials Delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387-94.
[23] Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and Locally Advanced Nonsmall-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Followup. Ann Oncol 2017;28 Suppl 4:iv1-21.
[24] Rodrigues G, Choy H, Bradley J, Rosenzweig KE, Bogart J, Curran WJ, et al. Adjuvant Radiation Therapy in Locally Advanced Non-small Cell Lung Cancer: Executive Summary of an American Society for Radiation Oncology (ASTRO) Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2015;5:149-55.
[25] Ramroth J, Cutter DJ, Darby SC, Higgins GS, Mcgale P, Partridge M, et al. Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer : Meta-Analysis of Randomized Trials. Radiat Oncol Biol 2016;96:736-47.
[26] Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A New Approach to Dose Escalation in Nonsmall-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2001;49:23-33.
[27] Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, et al. Effect of Overall Treatment Time on Outcomes after Concurrent Chemoradiation for Locally Advanced Non-small-Cell Lung Carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005;63:667-71.
[28] Withers HR, Taylor JM, Maciejewski B. The Hazard of Accelerated Tumor Clonogen Repopulation during Radiotherapy. Acta Oncol (Madr) 1988;27:131-46.
[29] Fowler J. Non-small Cell Lung Tumors Repopulate Rapidly during Radiation Therapy. Int J Radiat Oncol 2000;46:516-7.
[30] Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M. Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) Versus Conventional Radiotherapy in Non-small Cell Lung Cancer: Mature Data from the Randomised Multicentre Trial. Radiother Oncol 1999;52:137-48.
[31] Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final Results of the Randomized Phase III CHARTWEL-trial (ARO 97-1) Comparing Hyperfractionated-Accelerated Versus Conventionally Fractionated Radiotherapy in Non-small Cell Lung Cancer (NSCLC). Radiother Oncol 2011;100:76-85.
[32] Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60.
[33] Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G, et al. A Randomised Phase III Study of Accelerated or Standard Fraction Radiotherapy with or without Concurrent Carboplatin in Inoperable Non-small Cell Lung Cancer: Final Report of an Australian Multi-centre Trial. Radiother Oncol 1999;52:129-36.
[34] Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, et al. Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient data Meta-analysis. J Clin Oncol 2012;30:2788-97.
[35. National Institute for Health and Care Excellence N. Lung Cancer Diagnosis and Management (NG122). NICE Guidel 2019;2019:1-40.
[36] Prewett SL, Aslam S, Williams M V., Gilligan D. The Management of Lung Cancer: A UK Survey of Oncologists. Clin Oncol 2012;24:402-9.
[37] Kaster TS, Yaremko B, Palma DA, Rodrigues GB. Radical-intent Hypofractionated Radiotherapy for Locally Advanced Non-small-cell Lung Cancer: A Systematic Review of the Literature. Clin Lung Cancer 2015;16:71-9.
[38] De Ruysscher DK, Botterweck A, Dirx M, PijlsJohannesma M, Wanders R, Hochstenbag M, et al. Eligibility for Concurrent Chemotherapy and Radiotherapy of Locally Advanced Lung Cancer Patients: A Prospective, Population-Based Study. Ann Oncol 2009;20:98-102.
[39] Al-Shamsi HO, Al Farsi A, Ellis PM. Stage III Nonsmall-cell Lung Cancer: Establishing a Benchmark for the Proportion of Patients Suitable for Radical Treatment. Clin Lung Cancer 2014;15:274-80.
[40] Valeriani M, Marinelli L, Nicosia L, Reverberi C, De Sanctis V, Mollo D, et al. Locally Advanced Inoperable Primary or Recurrent Non-small Cell Lung Cancer Treated with 4-Week Hypofractionated Radiation Therapy (3 Gy/ Fraction). Radiol Med 2019;124:1324-32.
[41] de Dios NR, Sanz X, Foro P, Membrive I, Reig A, Ortiz A, et al. Accelerated Hypofractionated Radiation Therapy (AHRT) for Non-small-Cell Lung Cancer: Can we Leave Standard Fractionation? Clin Transl Oncol 2017;19:440-7.
[42] Din OS, Harden SV, Hudson E, Mohammed N, PembertonLS, Lester JF, et al. Accelerated Hypo-fractionated Radiotherapy for Non Small Cell Lung Cancer: Results from 4 UK Centres. Radiother Oncol 2013;109:8-12.
[43] Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R. Accelerated Hypofractionated Radiation Therapy Compared to Conventionally Fractionated Radiation Therapy for the Treatment of Inoperable Non-small Cell Lung Cancer. Radiat Oncol 2012;7:33.
[44] Iocolano M, Wild AT, Hannum M, Zhang Z, Simone CB, Gelblum D, et al. Hypofractionated vs. Conventional Radiation Therapy for Stage III Non-small Cell Lung Cancer Treated without Chemotherapy. Acta Oncol (Madr) 2020;59:164-70.
[45] Parisi G, Mazzola R, Ciammella P, Timon G, Fozza A, Franceschini D, et al. Hypofractionated Radiation Therapy in the Management of Locally Advanced NSCLC: A Narrative Review of the Literature on Behalf of the Italian Association of Radiation Oncology (AIRO) Lung Working Group. Radiol Med 2019;124:136-44.
[46] Westover KD, Loo BW, Gerber DE, Iyengar P, Choy H, Diehn M, et al. Precision Hypofractionated Radiation Therapy in Poor Performing Patients with Non-small Cell Lung Cancer: Phase 1 Dose Escalation Trial. Int J Radiat Oncol Biol Phys 2015;93:72-81.
[47] Choy H, Timmerman RD, Saunders MW, Court LE, Patel MK, Li Y, et al. A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patients an Interim Analysis. Int J Radiat Oncol 2016;96:E451.
[48] Kong C, Zhu X, Shi M, Wang L, Chen C, Tao H, et al. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020;107:710-9.
[49] Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, et al. Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy employing Optimized (Hypofractionated) Radiotherapy to Foster Durvalumab Efficacy: Study Protocol of the TRADE-hypo Trial. BMC Cancer 2020;20:806.
[50] NCT04249362 C go. I. Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART); 2020.
[51] Kumar S, Chmura S, Robinson C, Lin SH, Gadgeel SM, Donington J, et al. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. J Thorac Oncol 2020;15:1137-46.
[52] Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP Consensus Guideline on Implementation and Practice of Stereotactic Body Radiotherapy for Peripherally Located Early Stage Non-small Cell Lung Cancer. Radiother Oncol 2017;124:11-7.
[53] Faivre-finn C, Fenwick JD, Franks KN, Harrow S, Hatton MQ, Hiley C, et al. Reduced Fractionation in Lung Cancer Patients Treated with Curativeintent Radiotherapy during the COVID-19 Pandemic. Clin Oncol 2020;32:481-9.
[54] Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, et al. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol 2018;101:177-85.
[55] Lin Q, Liu YE, Ren XC, Wang N, Chen XJ, Wang DY, et al. Dose Escalation of Accelerated Hypofractionated Three-dimensional Conformal Radiotherapy (at 3 Gy/ Fraction) with Concurrent Vinorelbine and Carboplatin Chemotherapy in Unresectable Stage III Non-small-cell Lung Cancer: A Phase I Trial. Radiat Oncol 2013;8:1.
[56] Iqbal MS, Vashisht G, McMenemin R, Atherton P, McDonaldF, Simmons T, et al. Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review. Clin Oncol 2019;31:e1-10.
[57] Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomised Trial of Sequential Versus Concurrent Chemo-radiotherapy in Patients with Inoperable Non-small Cell Lung Cancer (EORTC 08972-22973). Eur J Cancer 2007;43:114-21.
[58] Uitterhoeve AL, Koolen MG, van Os RM, Koedooder K, van de Kar M, Pieters BR, et al. Accelerated high-dose Radiotherapy Alone or Combined with Either Concomitant or Sequential Chemotherapy; Treatments of Choice in Patients with Non-Small Cell Lung Cancer. Radiat Oncol 2007;2:1-10.
[59] Walraven I, Van Den Heuvel M, Van Diessen J, Schaake E, Uyterlinde W, Aerts J, et al. Long-term Follow-up of Patients with Locally Advanced Non-small Cell Lung Cancer Receiving Concurrent Hypofractionated Chemoradiotherapy with or without Cetuximab. Radiother Oncol 2016;118:442-6.
[60] Stam B, van der Bijl E, van Diessen J, Rossi MM, TijhuisA, Belderbos JS, et al. Heart Dose Associated with Overall Survival in Locally Advanced NSCLC Patients Treated with Hypofractionated Chemoradiotherapy. Radiother Oncol 2017;125:62-5.
[61] Guckenberger M, Belka C, Bezjak A, Bradley J, Daly ME, Deruysscher D, et al. Practice Recommendations for Lung Cancer Radiotherapy during the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement; 2020.
[62] Zehentmayr F, Grambozov B, Kaiser J, Fastner G, Sedlmayer F. Radiation Dose Escalation with Modified Fractionation Schedules for Locally Advanced NSCLC: A Systematic Review. Thorac Cancer 2020;11:1375-85.
[63] Van Baardwijk A, Wanders S, Boersma L, Borger J, Öllers M, Dingemans AM, et al. Mature Results of an Individualized Radiation Dose Prescription Study Based on Normal Tissue Constraints in Stages I to III Non-smallcell Lung Cancer. J Clin Oncol 2010;28:1380-6.
[64] Cannon DM, Mehta MP, Adkison JB, Khuntia D, TraynorAM, Tomé WA, et al. Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in NonSmall-Cell Lung Cancer. J Clin Oncol 2013;31:4343-8.
[65] Landau DB, Hughes L, Baker A, Bates AT, Bayne MC, Counsell N, et al. IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2016;95:1367-77.
[66] Fenwick JD, Landau DB, Baker AT, Bates AT, Eswar C, Garcia-Alonso A, et al. Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020;106:733-42.
[67] Hatton MQ, Lawless CA, Faivre-Finn C, Landau D, Lester JF, Fenwick J, et al. Accelerated, Dose Escalated, Sequential Chemoradiotherapy in Non-small-cell lung Cancer (ADSCaN): A Protocol for a Randomised Phase II Study. BMJ Open 2019;9:e019903.
[68] Kong FM, Ten Haken RK, Schipper M, Frey KA, Hayman J, Gross M, et al. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced NonSmall-Cell Lung Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2017;3:1358-65.
[69] Lalezay F. The PET-Boost Trial: Isotoxic Homogeneous or FDG-Directed Dose Escalation in Stage II-III NSCLC. ESTRO Congress; 2020.
[70] Roach MC, Bradley JD, Robinson CG. Optimizing Radiation Dose and Fractionation for the Definitive Treatment of Locally Advanced Non-small Cell Lung Cancer. J Thorac Dis 2018;10:S2465-73.
[71] Kong FM. Randomized Phase Trial (RTOG1106) on Midtreatment PET/CT Guided Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer. IASLC 2020 WCLC; 2020.
[72] Scott JG, Sedor G, Scarborough JA, Kattan MW, Peacock J, Grass GD, et al. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. J Thorac Oncol 2021;16:428-38.
[73] Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic Ablative Radiotherapy Versus Standard Radiotherapy in Stage 1 Non-small-cell Lung Cancer (TROG 09.02 CHISEL): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet Oncol 2019;20:494-503.
[74] Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic Radiotherapy (SABR) for the Treatment of Primary Non-Small Cell Lung Cancer; Systematic Review and Comparison with a Surgical Cohort. Radiother Oncol 2013;109:1-7.
[75] Kumar S, Feddock J, Li X, Shearer AJ, Hall L, Shelton BJ, et al. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer. Radiat Oncol Biol 2017;99:652-9.
[76] Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, et al. Stereotactic Body Radiation Therapy Can Be Used Safely to Boost Residual Disease in Locally Advanced Non-Small Cell Lung Cancer : A Prospective Study. Radiat Oncol Biol 2013;85:1325-31.
[77] Hepel JT, Leonard KL, Safran H, Ng T, Taber A, KhurshidH, et al. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced NonSmall Cell Lung Cancer: A Phase 1 Dose Escalation Study. Int J Radiat Oncol Biol Phys 2016;12:1687-95.
[78] Hepel JT, Peter J, Hiatt JR, Patel S, Osibanjo O, Safran H, et al. Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer. Front Oncol 2012;2:124.
[79] Higgins KA, Pillai RN, Chen Z, Tian S, Zhang C, Patel P, et al. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. J Thorac Oncol 2017;12:1687-95.
[80] Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM. Dose Escalation with Stereotactic Body Radiation Therapy Boost for Locally Advanced Non Small Cell Lung Cancer. Radiat Oncol 2013;8:1-8.
[81] Nguyen NT, Isfahanian N, Pond G, Hanna W, Cutz JC, Wright J, et al. A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). Clin Lung Cancer 2017;18:436-40.e1.
[82] Singh AK, Hennon M, Ma SJ, Demmy TL, Picone A, Dexter EU, et al. A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) after Surgery for Stage III Nonsmall Cell Lung Cancer. BMC Cancer 2018;18:1183.
[83] Peulen H, Franssen G, Belderbos J, van der Bijl E, TijhuisA, Rossi M, et al. SBRT Combined with Concurrent Chemoradiation in Stage III NSCLC: Feasibility Study of the Phase I Hybrid Trial. Radiother Oncol 2020;142:224-9.
[84] Alcibar OL, Candini D, López-Campos F, Antequera MA, Macías VM, Conde AJ, et al. Time for Radioimmunotherapy: An Overview to Bring Improvements in Clinical Practice. Clin Transl Oncol 2019;2019:0123456789.
[85] Walshaw RC, Honeychurch J, Illidge TM. Stereotactic Ablative Radiotherapy and Immunotherapy Combinations: Turning the Future into Systemic Therapy? Br J Radiol 2016;89:20160472.
[86] Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III NonSmall Cell Lung (358). US National Library of Medicine; 2020. Available from: https://www.clinicaltrials.gov/ct2/ show/NCT03589547. [Last accessed on June 2020].